OLMA

NASDAQ 已收盘

Olema Oncology

7.15 USD
▲+0.09+1.27%
盘后 7.16 +0.14%
2026-11-19
市值
$615.00M
市盈率
—
EPS
-2.40
股息率
—
52 周区间
6.24 – 36.26
成交量
1.85M
Beta
2.02
目标价
35.50
52W 低 6.2452W 高 36.26
价格走势

公司简介

Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third...